In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Katherine Kurnit. Dr. Kurnit is an Assistant Professor at the University of Chicago in the section of Gynecologic Oncology. Her research interests include developmental therapeutics and early phase clinical trials for patients with gynecologic cancers.

Highlights:

Although surgical practices have changed over time, there is still much debate and no consistent consensus about timing or the use of new therapies such as HIPEC.

More options for upfront maintenance therapy are now available for ovarian cancer patients.

We need new treatment approaches for patients with platinum-resistant ovarian cancer.

Finding ways to ensure ovarian cancer care is safe, feasible, and cost-effective in many different settings (nationally and internationally) will be important.